Inventor · disambiguated record
Gottfried Himmler
Also filed as: HIMMLER GOTTFRIED
24 granted patents·30 pending applications·466 citations·filing 1994–2023
96Inventor score
Files withF-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTW M B H8IGENEON KREBS IMMUNTHERAPIE8HIMMLER GOTTFRIED7F STAR BIOTECH FORSCH & ENTW6F STAR THERAPEUTICS LTD4
Top patents by PatentIndex Score
54 records- 0192US9133274B2Method for engineering immunoglobulinsHIMMLER GOTTFRIED·Filed 2007·Granted Sep 15, 2015·16 cites·38 claims
- 0292US9045528B2Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regionsRUKER FLORIAN·Filed 2011·Granted Jun 2, 2015·21 cites·19 claims
- 0391US9651559B2Display of binding agentsF-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTW M B H·Filed 2014·Granted May 16, 2017·8 cites·9 claims
- 0491US8921279B2Display of binding agentsHIMMLER GOTTFRIED·Filed 2008·Granted Dec 30, 2014·13 cites·6 claims
- 0589US9856311B2Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regionsRUKER FLORIAN·Filed 2011·Granted Jan 2, 2018·12 cites·9 claims
- 0689US8859738B2Cytotoxic immunoglobulinHIMMLER GOTTFRIED·Filed 2009·Granted Oct 14, 2014·15 cites·4 claims
- 0788US6033881AMethod for one step isothermal non-transcription based amplification of nucleic acidsFiled 1996·Granted Mar 7, 2000·243 cites·17 claims
- 0886US10385118B2Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regionsF STAR BIOTECHNOLOGISCHE FORSCHUNGS UND ENTW M B H·Filed 2017·Granted Aug 20, 2019·4 cites·6 claims
- 0985US9255149B2Cytotoxic immunoglobulinF STAR BIOTECH FORSCH & ENTW·Filed 2015·Granted Feb 9, 2016·8 cites·30 claims
- 1085US5866694APeptides that induce antibodies which neutralize genetically divergent HIV-1 isolatesKATINGER HERMANN·Filed 1997·Granted Feb 2, 1999·52 cites·18 claims
- 1181US2023340696A1Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regionsF STAR THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1279US9636415B2Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergiesS-TARGET THERAPEUTICS GMBH·Filed 2013·Granted May 2, 2017·2 cites·15 claims
- 1379US7527789B2Use of a preparation based on an antibody directed against a tumor-associated glycosylationIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Granted May 5, 2009·9 cites·28 claims
- 1478US10189905B2Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergiesS TARGET THERAPEUTICS GMBH·Filed 2017·Granted Jan 29, 2019·1 cites·12 claims
- 1578US2024150495A1Novel Multivalent ImmunoglobulinsF STAR THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1673US10059777B2Secretory immunoglobulin complexHIMMLER GOTTFRIED·Filed 2013·Granted Aug 28, 2018·1 cites·18 claims
- 1773US5756674APeptides that induce antibodies which neutralize genetically divergent HIV-1 isolatesKATINGER HERMANN·Filed 1995·Granted May 26, 1998·31 cites·8 claims
- 1871US11084868B2Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regionsF STAR BIOTECHNOLOGISCHE FORSCHUNGS UND ENTW M B H·Filed 2019·Granted Aug 10, 2021·0 cites·7 claims
- 1971US9079765B2Nanoparticles comprising antigens and adjuvants, and immunogenic structuresHIMMLER GOTTFRIED·Filed 2005·Granted Jul 14, 2015·4 cites·26 claims
- 2070US11499249B2Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regionsF STAR THERAPEUTICS LTD·Filed 2019·Granted Nov 15, 2022·0 cites·13 claims
- 2170US2021388339A1Method for engineering immunoglobulinsF STAR BIOTECHNOLOGISCHE FORSCHUNGS UND ENTW M B H·Filed 2021·Application pending·0 cites
- 2265US5693752APeptides that induce antibodies which neutralize genetically divergent HIV-1 isolatesKATINGER HERMANN·Filed 1994·Granted Dec 2, 1997·22 cites·13 claims
- 2364US8034338B2Immunogenic recombinant antibodyIGENEON KREBS IMMUNTHERAPIE·Filed 2004·Granted Oct 11, 2011·4 cites·6 claims
- 2464US2009130125A1Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancerIGENEONG KREBS IMMUNTHERAPIE F·Filed 2008·Application pending·0 cites
- 2561US11827720B2Multivalent immunoglobulinsF STAR THERAPEUTICS LTD·Filed 2017·Granted Nov 28, 2023·0 cites·5 claims
- 2661US2005255116A1Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancerIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Application pending·0 cites
- 2760US7759464B2N-glycosylated antibodyGREENOVATION BIOTECH GMBH·Filed 2004·Granted Jul 20, 2010·0 cites·12 claims
- 2860US2017369868A1Method for engineering immunoglobulinsF-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTW M B H·Filed 2017·Application pending·0 cites
- 2957US2010009863A1Method for engineering t-cell receptorsF STAR BIOTECH FORSCH & ENTW·Filed 2007·Application pending·0 cites
- 3056US2013040836A1Methods for engineering t-cell receptorsSTAR BIOTECHNOLOGISCHE FORSCHUNGS UND ENTWICKLUNGSGES M B H F·Filed 2012·Application pending·0 cites
- 3156US2017247432A1Display of binding agentsF-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTW M B H·Filed 2017·Application pending·0 cites
- 3256US2014364592A1Cytotoxic immunoglobulinF STAR BIOTECH FORSCH & ENTW·Filed 2014·Application pending·0 cites
- 3355US10125197B2Cytotoxic immunoglobulinF STAR BIOTECHNOLOGISCHE FORSCHUNGS UND ENTW M B H·Filed 2016·Granted Nov 13, 2018·0 cites·32 claims
- 3455US2017015727A1Methods for engineering t-cell receptorsF-STAR BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTW M B H·Filed 2016·Application pending·0 cites
- 3554US2009181030A1Use of a preparation based on an antibody directed against a tumor-associated glycosylationIGENEON KREBS IMMUNTHERAPIE·Filed 2009·Application pending·0 cites
- 3654US2016000914A1Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancerGREENOVATION BIOTECH GMBH·Filed 2015·Application pending·0 cites
- 3754US2010048877A1Novel multivalent immunoglobulinsF STAR BIOTECH FORSCH & ENTW·Filed 2007·Application pending·0 cites
- 3853US2015376603A1Method for engineering immunoglobulinsF STAR BIOTECH FORSCH & ENTW·Filed 2015·Application pending·0 cites
- 3952US2005169929A1Use of a vaccine for active immunization against cancerFiled 2003·Application pending·0 cites
- 4052US2005181475A1Immunogenic monoclonal antibodyIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Application pending·0 cites
- 4151US2006018901A1Use of antibodies in a very low dose for the vaccination against cancerLOIBNER HANS·Filed 2005·Application pending·0 cites
- 4251US2006246056A1Immunotherapy of rectal cancerIGENEON KREBS IMMUNTHERAPIE·Filed 2004·Application pending·0 cites
- 4351US2015335738A1Secretory immunoglobulin deficiency treatment and prophlaxisHIMMLER GOTTFRIED·Filed 2013·Application pending·0 cites
- 4450US2006127403A1Use of antibodies against tumor-associated antigenIGENEON KREBS IMMUNTHERAPIE·Filed 2003·Application pending·0 cites
- 4550US2010143342A1Bispecific molecule binding tlr9 and cd32 and comprising a t cell epitope for treatment of allergiesF STAR BIOTECH FORSCH & ENTW·Filed 2007·Application pending·0 cites
- 4648US2004151717A1Use of polyclonal immunoglobulinsFiled 2002·Application pending·0 cites
- 4747US8323650B2Method of treating lewis Y-expressing tumorsSCHUSTER MANFRED·Filed 2010·Granted Dec 4, 2012·0 cites·20 claims
- 4846US2010310551A1Immunogenic, monoclonal antibodyMERIDIAN BIOPHARMACEUTICALS GMBH·Filed 2010·Application pending·0 cites
- 4945US2007243201A1Method for Selecting Epitopes for ImmunotherapyIGENEON KREBS IMMUNTHERAPIE·Filed 2004·Application pending·0 cites
- 5043US2017334992A9Bispecific molecule binding tlr9 and cd32 and comprising a t cell epitope for treatment of allergiesS-TARGET THERAPEUTICS GMBH·Filed 2016·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →